about
Image-Guided Radiotherapy Using a Modified Industrial Micro-CT for Preclinical ApplicationsSimultaneous iterative reconstruction of emission and attenuation images in positron emission tomography from emission data only.Quantitative image reconstruction in PET from emission data only using cluster analysis.Treatment planning in PRRT based on simulated PET data and a PBPK model. Determination of accuracy using a PET noise model.A Monte Carlo based source model for dose calculation of endovaginal TARGIT brachytherapy with INTRABEAM and a cylindrical applicator.Quantitative and qualitative assessment of Yttrium-90 PET/CT imaging.[11C]choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy.A survey of PET activity in Germany during 1999.Physiologically Based Pharmacokinetic Modeling Is Essential in 90Y-Labeled Anti-CD66 RadioimmunotherapyComparison of breast simultaneous integrated boost (SIB) radiotherapy techniques.Investigating the Effect of Ligand Amount and Injected Therapeutic Activity: A Simulation Study for 177Lu-Labeled PSMA-Targeting Peptides.Imaging of Orthotopic Glioblastoma Xenografts in Mice Using a Clinical CT Scanner: Comparison with Micro-CT and HistologyComparison of breast sequential and simultaneous integrated boost using the biologically effective dose volume histogram (BEDVH)Dependence of treatment planning accuracy in peptide receptor radionuclide therapy on the sampling scheduleCumulative radiation exposure from imaging procedures and associated lifetime cancer risk for patients with lymphoma.The HIV-derived protein Vpr52-96 has anti-glioma activity in vitro and in vivo.Treatment planning in molecular radiotherapy.Technical prerequisites and imaging protocols for CT perfusion imaging in oncology.Prediction of time-integrated activity coefficients in PRRT using simulated dynamic PET and a pharmacokinetic model.Physiologically based pharmacokinetic modeling of (18)F-SiFAlin-Asp3-PEG1-TATE in AR42J tumor bearing mice.Investigation of the imaging characteristics of the ALBIRA II small animal PET system for 18F, 68Ga and 64Cu.In vivo micro-CT imaging of untreated and irradiated orthotopic glioblastoma xenografts in mice: capabilities, limitations and a comparison with bioluminescence imaging.Comparison of five cluster validity indices performance in brain [18 F]FET-PET image segmentation using k-means.Time-integrated activity coefficient estimation for radionuclide therapy using PET and a pharmacokinetic model: A simulation study on the effect of sampling schedule and noise.New molecular markers for prostate tumor imaging: a study on 2-methylene substituted fatty acids as new AMACR inhibitors.Sensitivity Analysis of a Physiologically Based Pharmacokinetic Model Used for Treatment Planning in Peptide Receptor Radionuclide Therapy.Optimized Peptide Amount and Activity for ⁹⁰Y-Labeled DOTATATE Therapy.The role of patient-based treatment planning in peptide receptor radionuclide therapy.Knowledge-based radiation therapy (KBRT) treatment planning versus planning by experts: validation of a KBRT algorithm for prostate cancer treatment planningPopulation-Based Modeling Improves Treatment Planning Before (90)Y-Labeled Anti-CD66 Antibody Radioimmunotherapy.The NUKDOS software for treatment planning in molecular radiotherapy.A single-source photon source model of a linear accelerator for Monte Carlo dose calculation.Potential of optimal preloading in anti-CD20 antibody radioimmunotherapy: an investigation based on pharmacokinetic modeling.Imaging of activated microglia with PET and [11C]PK 11195 in corticobasal degeneration.Dependence of image quality on acquisition time for the PET/CT Biograph mCT.Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures.Improving anti-CD45 antibody radioimmunotherapy using a physiologically based pharmacokinetic model.Evaluation of pyrimidine metabolising enzymes and in vitro uptake of 3'-[(18)F]fluoro-3'-deoxythymidine ([(18)F]FLT) in pancreatic cancer cell lines.FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters.Optimal preloading in radioimmunotherapy with anti-cD45 antibody.
P50
Q27307856-8592E0CF-1002-483F-B321-439471E29B9EQ30734127-19F91DA1-CAEE-4235-AF44-5505FB6D8F2DQ30888777-B63CDF51-7839-49BD-99DE-408BBBB56BE1Q31144631-995210FA-0305-420D-86CE-FD917F61BF09Q34319186-744AB468-9CAF-42FC-A802-11A12589A328Q34450157-985E9CB6-91DA-4C03-8892-89E93A51F78DQ34683467-0A102E96-9942-4FF7-9C27-EF4ADDBE184DQ34781795-973AA717-2F87-4819-976C-4E2929EA68FDQ35641211-50CFA669-F151-43E9-9485-F839D3E751CFQ35830844-98A408D4-7FA3-4F38-B5EC-81D4FA0EE61AQ36128368-8B810D4B-B17A-4569-9AD3-07FCCB2CE7A2Q36187408-1CFFCFF8-1178-4086-8163-7A63A3921135Q36529659-674385DA-C644-407E-9A6F-74B3339D8702Q36729683-E0383275-6E65-4657-8EF6-264BAD50044CQ37342972-C17812D3-BD3F-48D0-A402-A4C74BC036A9Q37564463-269E0ED8-9967-40D7-A0C5-F4EA1543828EQ38099899-A23672DE-947E-4E73-9521-C38183C5C1A5Q38542135-3E304EB4-4FB5-4E33-895E-323384584066Q38664082-D0873CF3-496F-4441-A665-8C48DC607515Q38779242-FAF71765-D2A6-4A94-86BE-7917107187E1Q38835779-405B59A9-D2BC-46A1-B87E-E8975AE02CB4Q38918192-AD33BEC4-7366-4713-8D64-285F63D597DEQ39012562-DF718029-C993-4A72-9D2E-39B5C78B54F7Q39430065-511EE1E1-AF50-45AF-8706-C4529574C88CQ39496005-E5EC6F7D-7787-4869-B1D1-82CA223DC550Q39610639-AF1ADC59-A04C-408E-B5BC-C5A2FDEC4C2BQ40200665-6F9B9B96-A6B6-448E-915D-36F1CD8CA894Q40311407-6B71026F-A7D0-4862-9622-851F6888098DQ40706704-94BF4421-8D8F-42CA-AEDD-DB4C86C0FCDFQ40739783-3590DFDB-ACD2-4EC9-BC7F-F1B714980740Q41190790-B8349D83-E01E-4DB3-BED4-0E08385F9A15Q41495131-FBFDC4EF-4201-4E0F-87CA-C5D924022A22Q41945014-94BFE948-F9E7-45A5-8A02-BB797C570131Q42464658-A0919F6F-6A65-4EE1-AD67-3818903D2558Q43442882-B179C007-3463-4DF8-A08A-9D308D27D518Q43584076-4A655C16-3F93-4FFC-BFCE-14198A73AF56Q43692160-07F5904D-BFDD-40FB-A084-2932191354AAQ44112084-30FEC76D-BAA4-416B-8FFB-A4FA51D68C0AQ44149763-998B13ED-4B1A-4E41-93EA-7CC63413B810Q44286280-F19E95BA-443F-4F39-A15A-FDD7E04573E9
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Gerhard Glatting
@ast
Gerhard Glatting
@en
Gerhard Glatting
@es
Gerhard Glatting
@nl
Gerhard Glatting
@sl
type
label
Gerhard Glatting
@ast
Gerhard Glatting
@en
Gerhard Glatting
@es
Gerhard Glatting
@nl
Gerhard Glatting
@sl
prefLabel
Gerhard Glatting
@ast
Gerhard Glatting
@en
Gerhard Glatting
@es
Gerhard Glatting
@nl
Gerhard Glatting
@sl
P214
P106
P1153
7003887617
P214
P31
P496
0000-0001-7916-1576
P735
P7859
viaf-309724714